Vertex Pharmaceuticals (VRTX)
Create an AlertVertex Pharmaceuticals Enterprise Value:
17.13B for June 17, 2013Vertex Pharmaceuticals Historical Enterprise Value Data
Pro Data ExportThere is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| June 17, 2013 | 17.13B |
| June 14, 2013 | 17.13B |
| June 13, 2013 | 17.65B |
| June 12, 2013 | 17.12B |
| June 11, 2013 | 17.37B |
| June 10, 2013 | 17.76B |
| June 7, 2013 | 17.69B |
| June 6, 2013 | 16.63B |
| June 5, 2013 | 16.39B |
| June 4, 2013 | 16.70B |
| June 3, 2013 | 16.92B |
| May 31, 2013 | 17.14B |
| May 30, 2013 | 17.76B |
| May 29, 2013 | 16.71B |
| May 28, 2013 | 16.63B |
| May 24, 2013 | 16.71B |
| May 23, 2013 | 16.73B |
| May 22, 2013 | 16.72B |
| May 21, 2013 | 16.95B |
| May 20, 2013 | 16.48B |
| May 17, 2013 | 16.95B |
| May 16, 2013 | 16.60B |
| May 15, 2013 | 16.94B |
| May 14, 2013 | 17.29B |
| May 13, 2013 | 17.10B |
| May 10, 2013 | 17.16B |
| May 9, 2013 | 16.35B |
| May 8, 2013 | 16.05B |
| May 7, 2013 | 16.27B |
| May 6, 2013 | 16.46B |
| May 3, 2013 | 16.18B |
| May 2, 2013 | 16.56B |
| May 1, 2013 | 16.36B |
| April 30, 2013 | 16.36B |
| April 29, 2013 | 16.69B |
| April 26, 2013 | 16.85B |
| April 25, 2013 | 16.91B |
| April 24, 2013 | 17.07B |
| April 23, 2013 | 17.62B |
| April 22, 2013 | 17.35B |
| April 19, 2013 | 18.07B |
| April 18, 2013 | 10.91B |
| April 17, 2013 | 11.17B |
| April 16, 2013 | 11.24B |
| April 15, 2013 | 11.17B |
| April 12, 2013 | 11.54B |
| April 11, 2013 | 11.34B |
| April 10, 2013 | 11.34B |
| April 9, 2013 | 10.85B |
| April 8, 2013 | 10.88B |
About Enterprise Value
Click "Learn More" below to see how YCharts calculates Enterprise Value.
Enterprise Value (EV) is a valuation metric alternative to traditional market capitalization that reflects the market value of an entire business. Like market cap, EV is a measure of what the market believes a company is worth. Enterprise value captures the cost of an entire business, including debt and equity. It is a sum of claims of all preferred shareholders, debt holders, security holders, common equity holders, and minority shareholders - unlike market cap, which only captures the total value of common equity securities.
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Learn More
VRTX Enterprise Value Benchmarks
| Companies | |
|---|---|
| Celldex Therapeutics | 1.126B |
| Regeneron Pharmaceuticals | 23.21B |
| Gilead Sciences | 85.02B |
VRTX Enterprise Value Rankings
| Overall |
96th percentile 668 of 16770 |
| Sector |
96th percentile 55 of 1408 in Healthcare |
| Industry |
96th percentile 15 of 453 in Biotechnology |
VRTX Enterprise Value Range, Past 5 Years
| Minimum | 2.485B | Oct 28 2008 |
| Maximum | 18.07B | Apr 19 2013 |
| Average | 7.524B |
